Eli Lilly surpasses Novo's golden diabetes drug

US pharmaceutical firm Eli Lilly has presented its long-awaited data for drug candidate tirzepatide in a direct comparison study with Novo Nordisk's semaglutide. The US candidate takes top prize.

Photo: Mike Blake/REUTERS / X00030

US firm Eli Lilly is well on the way to overtaking Danish pharmaceutical flagship Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs